비교리스트

 카트 문의
시장보고서
상품코드
1587809

인터류킨 억제제 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 투여 경로별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Interleukin Inhibitors Market Size, Share & Trends Analysis Report By Type, By Route Of Administration (SC, IV), By Application (RA, Psoriasis, IBD, Asthma), By End-use, By Region, And Segment Forecasts, 2025 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

인터류킨 억제제 시장 성장 및 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 인터류킨 억제제 시장 규모는 2025년부터 2030년까지 17.3%의 CAGR을 기록하며 2030년까지 722억 달러에 달할 것으로 예상됩니다.

이러한 배경에는 후기 파이프라인 의약품의 출시가 예정된 강력한 파이프라인이 있습니다.

이 시장의 치료 환경은 안전성, 유효성, 내약성 측면에서 우열을 가리기 위해 의약품을 직접 비교 시험으로 비교하게 되면서 경쟁이 치열해지고 있습니다. 예를 들어, UCB의 비멕주맙은 현재 심상성 건선을 적응증으로 하는 휴미라(시험명: BE SURE), 스텔라라(BE VIVID), 코센틱스(BE RADIANT)에 대한 3건의 임상시험이 진행 중입니다.

또한, 다양한 임상시험에 대한 투자 증가와 신규 분자 개발을 위한 제약기업과 연구기관의 전략적 제휴는 인터류킨 억제제 시장의 성장에 기여하는 주요 요인 중 하나입니다. 예를 들어, Genentech(F. Hoffman-La Roche社)는 매사추세츠 종합병원과 함께 거대세포성 동맥염 치료제 Actemra(토실리주맙)의 개발을 위해 공동연구를 진행하고 있습니다.

다양한 자가면역질환과 그 치료 옵션에 대한 소비자의 인식이 높아짐에 따라 수요가 증가할 것으로 예상됩니다. 예를 들어, 아일랜드 관절염 협회(Arthritis Ireland)는 류마티스 관절염의 다양한 치료 옵션과 조기 진단의 중요성에 대해 일반 대중을 대상으로 류마티스 관절염에 대한 인식 개선 캠페인을 시작했습니다. 또한, 유럽 크론병 및 궤양성 대장염 협회(European Federation of Crohn's &Ulcerative Colitis Association)는 염증성 장질환(IBD)을 앓고 있는 환자들의 인식을 높이기 위해 다양한 노력을 기울이고 있습니다.

인터류킨 억제제 시장 보고서 하이라이트

  • 용도별로는 건선 분야가 2024년 37.0%의 점유율로 시장을 주도했습니다.
  • 2024년에는 IL-23 억제제가 건선, IBD 등 자가면역질환 치료에 효과적이라는 점에서 27.5%의 매출 점유율로 시장을 선도했습니다.
  • 유형별로는 IL-17 억제제가 예측 기간 동안 16.1%의 높은 CAGR을 기록할 것으로 예상됩니다.
  • 아시아태평양은 헬스케어 인프라의 개선과 가처분 소득 증가로 인해 예측 기간 동안 가장 빠른 성장세를 보일 것으로 예상됩니다.
  • IL-억제제는 가격이 비싸지만, 유리한 상환 정책으로 저렴한 가격을 실현하여 시장 침투를 촉진할 것으로 보입니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 인터류킨 억제제 시장 변수, 동향, 범위

  • 시장 계통 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • 비즈니스 환경 분석
    • 업계 분석 - Porter's Five Forces 분석
    • PESTLE 분석

제4장 인터류킨 억제제 시장 : 유형 비즈니스 분석

  • 유형별 시장 점유율, 2024년과 2030년
  • 유형 부문 대시보드
  • 시장 규모와 예측 및 동향 분석, 유형별, 2018-2030년
  • IL-1 억제제
  • IL-2 억제제
  • IL-5 억제제
  • IL-6 억제제
  • IL-17 억제제
  • IL-23 억제제
  • 기타

제5장 인터류킨 억제제 시장 : 투여 경로 비즈니스 분석

  • 투여 경로 시장 점유율, 2024년과 2030년
  • 투여 경로 부문 대시보드
  • 시장 규모와 예측 및 동향 분석, 투여 경로별, 2018-2030년
  • 피하(SC)
  • 정맥내(IV)

제6장 인터류킨 억제제 시장 : 용도 비즈니스 분석

  • 용도 시장 점유율, 2024년 및 2030년
  • 용도 부문 대시보드
  • 시장 규모와 예측 및 동향 분석, 용도별, 2018-2030년
  • 류마티스 관절염
  • 건선
  • 염증성 장질환(IBD)
  • 천식
  • 기타

제7장 인터류킨 억제제 시장 : 최종 용도 비즈니스 분석

  • 최종 용도 시장 점유율, 2024년 및 2030년
  • 최종 용도 부문 대시보드
  • 시장 규모와 예측 및 동향 분석, 최종 용도별, 2018-2030년
  • 병원
  • 전문 클리닉
  • 기타

제8장 인터류킨 억제제 시장 : 유형, 투여 경로, 용도, 최종 용도별 지역 추정·동향 분석

  • 지역별 시장 점유율 분석, 2024년 및 2030년
  • 지역 시장 대시보드
  • 시장 규모, 예측 동향 분석, 2018-2030년 :
  • 북미
    • 국가별, 2018-2030년
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 국가별, 2018-2030년
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 노르웨이
    • 덴마크
    • 스웨덴
  • 아시아태평양
    • 국가별, 2018-2030년
    • 일본
    • 중국
    • 인도
    • 한국
    • 호주
    • 태국
  • 라틴아메리카
    • 국가별, 2018-2030년
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 국가별, 2018-2030년
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트
    • 쿠웨이트

제9장 경쟁 상황

  • 참여자 개요
  • 기업의 시장 포지션 분석
  • 기업 분류
  • 전략 매핑
  • 기업 개요/상장 기업
    • Novartis AG
    • AbbVie Inc.
    • Eli Lilly and Company
    • Regeneron Pharmaceuticals Inc.
    • Johnson & Johnson Services, Inc.
    • F. Hoffmann-La Roche Ltd
    • AstraZeneca
    • Bausch Health Companies Inc.
    • GlaxoSmithKline plc
    • Teva Pharmaceutical Industries Ltd
ksm 24.11.25

Interleukin Inhibitors Market Growth & Trends:

The global interleukin inhibitors market size is expected to reach USD 72.2 billion by 2030, registering a CAGR of 17.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. This can be attributed to a strong pipeline with upcoming launches of late-stage pipeline drugs.

The therapeutic landscape in this market is becoming increasingly competitive, as drugs are compared in head-to-head trials to determine superiority in terms of safety, efficacy, and tolerance. For instance, UCB's bimekizumab is currently under investigation in three such trials against Humira (trial name: BE SURE), Stelara (BE VIVID), and Cosentyx (BE RADIANT)-indicated for plaque psoriasis.

Furthermore, increasing investments on various clinical trials and strategic alliances between pharmaceutical companies and research organizations for development of novel molecules are few major contributors to interleukin inhibitors market growth. For instance, Genentech (F. Hoffmann-La Roche Ltd.) has collaborated with Massachusetts General Hospital for developing Actemra (tocilizumab) for the treatment of giant cell arteritis.

Rise in consumer awareness about various autoimmune diseases and their treatment options is anticipated to impel demand. For instance, Arthritis Ireland launched an awareness campaign for rheumatoid arthritis, educating the public about different treatment options and significance of early diagnosis. In addition, the European Federation of Crohn's & Ulcerative Colitis Association offers various initiatives to create awareness among patients suffering from Inflammatory Bowel Disease (IBD).

Interleukin Inhibitors Market Report Highlights:

  • By application, the psoriatic segment leading the market and accounted for a share of 37.0% in 2024
  • In 2024, IL-23 inhibitors led the market with a revenue share of 27.5%, due to their efficacy in treating autoimmune diseases, such as psoriasis and IBD.
  • By type, IL-17 inhibitors are expected to witness a significant CAGR of 16.1% over the forecast period.
  • Asia Pacific is expected to exhibit the fastest regional growth over the forecast period, fueled by enhanced healthcare infrastructure and growing disposable incomes.
  • Despite the high price of IL-inhibitors, favorable reimbursement policies are likely to provide affordability and support market penetration.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Route of Administration
    • 1.2.3. Application
    • 1.2.4. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Interleukin Inhibitors Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Interleukin Inhibitors Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. IL-1 Inhibitors
    • 4.4.1. IL-1 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.5. IL-2 Inhibitors
    • 4.5.1. IL-2 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.6. IL-5 Inhibitors
    • 4.6.1. IL-5 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.7. IL-6 Inhibitors
    • 4.7.1. IL-6 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.8. IL-17 Inhibitors
    • 4.8.1. IL-17 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.9. IL-23 Inhibitors
    • 4.9.1. IL-23 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Interleukin Inhibitors Market: Route of Administration Business Analysis

  • 5.1. Route of Administration Market Share, 2024 & 2030
  • 5.2. Route of Administration Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 5.4. Subcutaneous (SC)
    • 5.4.1. Subcutaneous (SC) Market, 2018 - 2030 (USD Million)
  • 5.5. Intravenous (IV)
    • 5.5.1. Intravenous (IV) Market, 2018 - 2030 (USD Million)

Chapter 6. Interleukin Inhibitors Market: Application Business Analysis

  • 6.1. Application Market Share, 2024 & 2030
  • 6.2. Application Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 6.4. Rheumatoid Arthritis
    • 6.4.1. Rheumatoid Arthritis Market, 2018 - 2030 (USD Million)
  • 6.5. Psoriasis
    • 6.5.1. Psoriasis Market, 2018 - 2030 (USD Million)
  • 6.6. Inflammatory Bowel Disease (IBD)
    • 6.6.1. Inflammatory Bowel Disease (IBD) Market, 2018 - 2030 (USD Million)
  • 6.7. Asthma
    • 6.7.1. Asthma Market, 2018 - 2030 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Interleukin Inhibitors Market: End Use Business Analysis

  • 7.1. End Use Market Share, 2024 & 2030
  • 7.2. End Use Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 7.4. Hospitals
    • 7.4.1. Hospitals Market, 2018 - 2030 (USD Million)
  • 7.5. Specialty Clinics
    • 7.5.1. Specialty Clinics Market, 2018 - 2030 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Interleukin Inhibitors Market: Regional Estimates & Trend Analysis by Type, Route of Administration, Application, and End Use

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Interleukin Inhibitors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Regulatory Framework
      • 8.4.2.3. Competitive Insights
      • 8.4.2.4. U.S. Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Regulatory Framework
      • 8.4.3.3. Competitive Insights
      • 8.4.3.4. Canada Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Regulatory Framework
      • 8.4.4.3. Competitive Insights
      • 8.4.4.4. Mexico Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Interleukin Inhibitors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Regulatory Framework
      • 8.5.2.3. Competitive Insights
      • 8.5.2.4. UK Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Regulatory Framework
      • 8.5.3.3. Competitive Insights
      • 8.5.3.4. Germany Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Regulatory Framework
      • 8.5.4.3. Competitive Insights
      • 8.5.4.4. France Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Regulatory Framework
      • 8.5.5.3. Competitive Insights
      • 8.5.5.4. Italy Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Regulatory Framework
      • 8.5.6.3. Competitive Insights
      • 8.5.6.4. Spain Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Norway
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Regulatory Framework
      • 8.5.7.3. Competitive Insights
      • 8.5.7.4. Norway Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Denmark
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Regulatory Framework
      • 8.5.8.3. Competitive Insights
      • 8.5.8.4. Denmark Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Sweden
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Regulatory Framework
      • 8.5.9.3. Competitive Insights
      • 8.5.9.4. Sweden Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Interleukin Inhibitors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Regulatory Framework
      • 8.6.2.3. Competitive Insights
      • 8.6.2.4. Japan Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory Framework
      • 8.6.3.3. Competitive Insights
      • 8.6.3.4. China Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory Framework
      • 8.6.4.3. Competitive Insights
      • 8.6.4.4. India Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. South Korea
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory Framework
      • 8.6.5.3. Competitive Insights
      • 8.6.5.4. South Korea Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. Australia
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Regulatory Framework
      • 8.6.6.3. Competitive Insights
      • 8.6.6.4. Australia Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Regulatory Framework
      • 8.6.7.3. Competitive Insights
      • 8.6.7.4. Thailand Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Interleukin Inhibitors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Regulatory Framework
      • 8.7.2.3. Competitive Insights
      • 8.7.2.4. Brazil Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Regulatory Framework
      • 8.7.3.3. Competitive Insights
      • 8.7.3.4. Argentina Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA Interleukin Inhibitors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Regulatory Framework
      • 8.8.2.3. Competitive Insights
      • 8.8.2.4. South Africa Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Regulatory Framework
      • 8.8.3.3. Competitive Insights
      • 8.8.3.4. Saudi Arabia Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Regulatory Framework
      • 8.8.4.3. Competitive Insights
      • 8.8.4.4. UAE Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Regulatory Framework
      • 8.8.5.3. Competitive Insights
      • 8.8.5.4. Kuwait Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Novartis AG
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. AbbVie Inc.
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Eli Lilly and Company
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Regeneron Pharmaceuticals Inc.
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Johnson & Johnson Services, Inc.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. F. Hoffmann-La Roche Ltd
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. AstraZeneca
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Bausch Health Companies Inc.
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. GlaxoSmithKline plc
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Teva Pharmaceutical Industries Ltd
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제